Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis

INTRODUCTION: Diroximel fumarate (DRF) is a next-generation oral fumarate that is indicated in the USA for relapsing forms of multiple sclerosis (MS). A joint population pharmacokinetic model was developed for the major active metabolite (monomethyl fumarate, MMF) and the major inactive metabolite (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchimanchi, Mita, Bockbrader, Howard, Dolphin, Nancy, Epling, Daniel, Quinlan, Lauren, Chapel, Sunny, Penner, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857385/
https://www.ncbi.nlm.nih.gov/pubmed/35041178
http://dx.doi.org/10.1007/s40120-021-00316-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857385/
https://www.ncbi.nlm.nih.gov/pubmed/35041178
http://dx.doi.org/10.1007/s40120-021-00316-6

Ejemplares similares